Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
J&J/Protagonist’s JNJ-2113 Advancing To Pivotal Psoriasis Trial But Efficacy Questions Remain
The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.
Keeping Track: Some Calm Before The Storm
The latest drug development news and highlights from our US FDA Performance Tracker.
A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers
Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.